Haleon (HLN) Income from Continuing Operations (2021 - 2025)
Haleon's (HLN) quarterly Income from Continuing Operations came in at 1089263004.53 in Q4 2025, down 51.46% on a QoQ basis from 2244002608.77 in Q4 2023.
Haleon (HLN) Income from Continuing Operations (2021 - 2025) Analysis & Trends
Haleon (HLN) has 4 years of Income from Continuing Operations data on file, last reported at 1089263004.53 in Q4 2025.
- Quarterly Income from Continuing Operations changed N/A year-over-year to 1089263004.53 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 4803264177.11 (changed N/A YoY) and the FY2025 annual result came in at 2234679213.43, up 18.52% from the prior year.
- Income from Continuing Operations slipped to 1089263004.53 in Q4 2025, from 2244002608.77 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2244002608.77 in Q4 2023 to a low of 651960202.73 in Q2 2023.
- A 4-year average of 1502599088.91 and a median of 1457853310.52 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations declined 0.63% — and 2023, when it climbed 5.76%.
- Tracing HLN's Income from Continuing Operations over 4 years: stood at 2135248801.77 in 2021, then dropped by 0.63% to 2121827332.94 in 2022, then gained by 5.76% to 2244002608.77 in 2023, then plunged by 51.46% to 1089263004.53 in 2025.
- The last three Income from Continuing Operations figures came in at 1089263004.53 (Q4 2025), 2244002608.77 (Q4 2023), and 651960202.73 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.09 Bn |
| Dec 31, 2023 | 2.24 Bn |
| Jun 30, 2023 | 651.96 Mn |
| May 3, 2023 | 818.04 Mn |
| Dec 31, 2022 | 2.12 Bn |
| Sep 20, 2022 | 1.46 Bn |
| Dec 31, 2021 | 2.14 Bn |